Five-year data from the KEYNOTE–942 trial show that the personalized mRNA cancer vaccine intismeran autogene, combined with ...
Add Yahoo as a preferred source to see more of our stories on Google. Health and Human Services Secretary Robert F. Kennedy Jr. canceled $500 million of funding for research on mRNA vaccine technology ...
Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.
Add Yahoo as a preferred source to see more of our stories on Google. RFK Jr. canceled $500 million of funding for research on mRNA vaccine technology. Anadolu/Getty Images At a Sept. 4, 2025, hearing ...
Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.
In this free webinar, gain insight into the principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development. Attendees will learn how mRNA synthesis, LNP ...
Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: boosting the immune system to better fight tumors during cancer treatment.
Vaccines using mRNA technology weren’t immune to the latest round of federal research cuts. Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he’s pulling the plug on ...
Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...
Hosted on MSN
Are mRNA Vaccines Safe — and Should You Still Get a COVID Shot? Doctors on the Pros and Cons
With the U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. canceling nearly $500 million in mRNA vaccine research contracts on Tuesday, you may be wondering if mRNA vaccines are safe.
A new personalized mRNA melanoma vaccine developed by Moderna and Merck is showing promising results, cutting the risk of cancer recurrence nearly in half for high-risk patients.
Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results